Skip to main content

Hyundai intends to make micro SUV in India

Tinuku - Hyundai Motor India Ltd, the second largest carmaker in India, may introduce a micro sports utility vehicle (SUV) to consolidate its position and increase market share. Hyundai, which makes Creta, SantaFe and Tucson is planning to add more products, specifically under the sub four-metre category.

“We have a small SUV Creta, may be later, we may have a micro SUV also. We will have a very strong SUV line-up,” Y.K. Koo, managing director, Hyundai Motor India said at its Chennai factory.

Tinuku Hyundai intends to make micro SUV in India

“We will increase our product portfolio in the SUV segment and with Creta, we have tasted success as in the segment as well, as we continue to sell almost 10,000 units every month, which is great given the price point at which the vehicle is available,” added Koo.

Creta launched in 2015, now sells 8,000-10,000 units a month. Both Creta and Maruti Suzuki India Ltd’s Vitara Brezza have together displaced Mahindra & Mahindra as India’s leading utility vehicle manufacturer. Hyundai will focus on the compact segment with the launch of a small hatchback, while another product probably a compact SUV will be launched in the next financial year.

Koo said the company will target a leadership position in the compact segment with the upcoming products. The South Korean manufacturer currently has a capacity utilization of 99% and plans to look at a new capacity after 2020 by when the safety norms and emission norms will be introduced.

Exports from India in the form of completely-built units has come down significantly and will continue to decline since most countries are trying to promote vehicle imports in the form of completely or semi knocked down units. That will free up a lot of space for the Korean manufacturer.


Popular posts

Conservative cleric vice president candidate of Indonesia, abstentions rose

Tinuku - Indonesian President Joko Widodo chose an elderly Muslim cleric Ma'ruf Amin as vice presidential candidate for the 2019 presidential election to become a red record for human rights activists. The figure who actively strives to criminalize minorities and sexuality is seen as a way to reverse human rights enforcement.

Lokataru's director, Haris Azhar, is still campaigning not to elect the presidential and vice presidential candidates. The declaration of two candidate pairs, especially the choice by Joko Widodo to Ma'ruf Amin as vice president and presidential candidate Prabowo Subianto on Sandiaga Uno as vice president, strengthened the minds of human rights activists.

"It's still the same. In fact, it is increasingly proven. From a human rights perspective, all candidates are violators of human rights. So I think the four candidates are the same, not friendly to human rights, not friendly to the environment," said Azhar told to Deutsche Welle Indones…

Ant Financial entered Indonesia in partnership with Emtek

Tinuku - Alibaba Group’s Ant Financial Services is making its first foray into Indonesia with plans to launch a new mobile platform for payment and other financial services in partnership with a local firm.

Ant Financial, operator of China’s popular online payment platform Alipay, announced on Wednesday that it will set up a joint venture with Indonesian digital company Emtek.

Without disclosing the size of the investment, the two companies said the joint venture will leverage Ant Financial’s experience and know-how in mobile payment, digital financial innovations, risk control and cloud computing.

To begin with, the new payment platform will be offered on BBM, Indonesia’s most commonly used messenger application, which is operated by a subsidiary of Emtek and has a user base of over 63 million monthly active users.

“Ant Financial has proven know-how in delivering payment and other financial solutions to a large and growing mobile audience in China and enabling its partners globally, …

Samsung Bioepis and Takeda plans clinical trials new drug

Tinuku - Samsung Bioepis said Monday that it plans to soon start phase 1 clinical trials for its first new drug candidate in development with Japan’s Takeda Pharmaceutical, setting a fresh milestone in the South Korean drugmaker’s push into new drug development.

The therapeutic candidate, SB26, also known as TAK-671, is an ulinastatin-Fc fusion protein to treat severe acute pancreatitis. It is the first result of the new drug development collaboration partnership signed by the two companies in August 2017. Samsung Bioepis spokesperson confirmed the upcoming clinical trials will be held in the US only, though the exact start date for the trials remain undisclosed.

Samsung Bioepis said, the study, randomized, double-blind, placebo-controlled and involving single and multiple dose escalation, will assess the safety, tolerability and pharmacokinetics of intravenous injections of SB26 in healthy volunteers. The results of the study are expected in the third quarter of 2020.

“The upcoming c…

Indonesia eyes plan to help startups expand across southeast Asia

Tinuku - Indonesia wants southeast Asian nations to cooperate in helping startups in the region worth at least $1 billion expand outside their home countries, the communication minister said on Friday. The effort aims to keep foreign startups from dominating a market of 640 million people by assisting the region’s estimated seven to ten unicorns, or companies that have attained a valuation of $1 billion without tapping the stock markets.

“I’ve discussed this strategy with other ministers in Southeast Asia and have offered to everyone to adopt existing unicorns and have a presence in each other’s countries,” Minister of Communication Rudiantara said in an interview.

“I’m really passionate about the issue and have discussed it at our last Association of Southeast Asian Nations ministers’ meeting,” he said at his office, adding that he would discuss the matter again at the next meeting of ASEAN ministers in Bali.

The suggestion drew a positive response from ministers from Thailand and Si…